Synovial Tissue Response to Treatment in Psoriatic Arthritis

Overview

Journal Open Rheumatol J

Publisher Bentham Open

Specialty Rheumatology

Date 2012 Jan 27

PMID 22279513

Citations 2

Authors

Veronica Codullo

Iain B McInnes

Affiliations

Soon will be listed here.

Abstract

Following its validation and wide application in rheumatoid arthritis (RA), synovial tissue analysis has recently been applied to studies on Psoriatic Arthritis (PsA). Such studies aim to thereby clarify its distinctive features and the nature of specific responses upon administration of disease modifying anti-rheumatic drug (DMARD) or biologic agents. In consequence, insights to disease pathogenesis, drugs' mechanisms of action (MOA) and biomarkers of response have emerged. Data from pilot and open-label studies, and recently from randomized controlled trials, have helped in refining the therapeutic approaches to PsA patients, by improving understanding of MOA and in provision of biomarkers of response. The availability of less invasive and reproducible analysis techniques to obtain and evaluate synovial biopsies will further enhance the utility of this approach in due course.

Citing Articles

Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.

Cagnotto G, Bruschettini M, Strozyk A, Scire C, Compagno M Cochrane Database Syst Rev. 2025; 2:CD013614.

PMID: 39945386 PMC: 11822884. DOI: 10.1002/14651858.CD013614.pub2.

From Bed to Bench and Back: TNF-α, IL-23/IL-17A, and JAK-Dependent Inflammation in the Pathogenesis of Psoriatic Synovitis.

Silvagni E, Missiroli S, Perrone M, Patergnani S, Boncompagni C, Bortoluzzi A Front Pharmacol. 2021; 12:672515.

PMID: 34211394 PMC: 8241099. DOI: 10.3389/fphar.2021.672515.

Profile of certolizumab and its potential in the treatment of psoriatic arthritis.

Chimenti M, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R Drug Des Devel Ther. 2013; 7:339-48.

PMID: 23620660 PMC: 3633576. DOI: 10.2147/DDDT.S31658.

References

Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C . Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum. 2001; 44(1):186-95. DOI: 10.1002/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B. View

Goedkoop A, Kraan M, Picavet D, de Rie M, Teunissen M, Bos J . Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther. 2004; 6(4):R326-34. PMC: 464872. DOI: 10.1186/ar1182. View

Jongbloed S, Benson R, Nickdel M, Garside P, McInnes I, Brewer J . Plasmacytoid dendritic cells regulate breach of self-tolerance in autoimmune arthritis. J Immunol. 2009; 182(2):963-8. DOI: 10.4049/jimmunol.182.2.963. View

Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J . Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther. 2005; 7(3):R569-80. PMC: 1174942. DOI: 10.1186/ar1698. View

Jongbloed S, Lebre M, Fraser A, Gracie J, Sturrock R, Tak P . Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther. 2006; 8(1):R15. PMC: 1526567. DOI: 10.1186/ar1864. View

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54(8):2665-73. DOI: 10.1002/art.21972. View

Tassiulas I, Duncan S, Centola M, Theofilopoulos A, Boumpas D . Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol. 1999; 60(6):479-91. DOI: 10.1016/s0198-8859(99)00034-8. View

van Kuijk A, Reinders-Blankert P, Smeets T, Dijkmans B, Tak P . Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006; 65(12):1551-7. PMC: 1798447. DOI: 10.1136/ard.2005.050963. View

Smith M, Baeten D, Ulfgren A, McInnes I, FitzGerald O, Bresnihan B . Standardisation of synovial tissue infiltrate analysis: how far have we come? How much further do we need to go?. Ann Rheum Dis. 2005; 65(1):93-100. PMC: 1797968. DOI: 10.1136/ard.2005.036905. View

10.

Haringman J, Gerlag D, Zwinderman A, Smeets T, Kraan M, Baeten D . Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2004; 64(6):834-8. PMC: 1755544. DOI: 10.1136/ard.2004.029751. View

11.

Malaviya R, Sun Y, Tan J, Wang A, Magliocco M, Yao M . Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol. 2006; 55(4):590-7. DOI: 10.1016/j.jaad.2006.05.004. View

12.

van Kuijk A, Gerlag D, Vos K, Wolbink G, de Groot M, de Rie M . A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis. 2008; 68(8):1303-9. PMC: 2703703. DOI: 10.1136/ard.2008.091389. View

13.

Canete J, Celis R, Moll C, Izquierdo E, Marsal S, Sanmarti R . Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2008; 68(5):751-6. DOI: 10.1136/ard.2008.089284. View

14.

Smeets T, Kraan M, van Loon M, Tak P . Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum. 2003; 48(8):2155-62. DOI: 10.1002/art.11098. View

15.

Canete J, Celis R, Hernandez V, Pablos J, Sanmarti R . Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann Rheum Dis. 2009; 69(5):935-6. DOI: 10.1136/ard.2009.113233. View

16.

Wong K, Gladman D, Husted J, Long J, Farewell V . Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997; 40(10):1868-72. DOI: 10.1002/art.1780401021. View

17.

Takada K, Danning C, Kuroiwa T, Schlimgen R, Tassiulas I, Davis Jr J . Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects. Ann Rheum Dis. 2003; 62(11):1112-5. PMC: 1754350. DOI: 10.1136/ard.62.11.1112. View

18.

Nickoloff B, Nestle F . Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004; 113(12):1664-75. PMC: 420513. DOI: 10.1172/JCI22147. View

19.

Curran S, FitzGerald O, Costello P, Selby J, Kane D, Bresnihan B . Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by.... J Immunol. 2004; 172(3):1935-44. DOI: 10.4049/jimmunol.172.3.1935. View

20.

Costello P, Winchester R, Curran S, Peterson K, Kane D, Bresnihan B . Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol. 2001; 166(4):2878-86. DOI: 10.4049/jimmunol.166.4.2878. View